Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MRGPRX4 | Q96LA9 | 12/20 | 0.51 |
| ▸ | PLAU | P00749 | 2/20 | 0.47 |
| ▸ | ERN1 | O75460 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | XBP1 | P17861 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.45 |
| ▸ | CYSLTR1 | Q9Y271 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30929975 | 0.95 | MRGPRX4 (0.56) | MRGPRX4PLAUERN1 | |
| SCHEMBL30929974 | 0.91 | PLAU (0.47) | PLAUERN1NPC1MAPTRAB9A | |
| SCHEMBL30929966 | 0.90 | MRGPRX4 (0.58) | MRGPRX4NPC1GAAMAPTXBP1 | |
| SCHEMBL30929964 | 0.89 | MAPT (0.49) | PLAUNPC1MAPTRAB9ASMN1; SMN2 | |
| SCHEMBL30929972 | 0.86 | SMPD1 (0.49) | MRGPRX4PLAUERN1MAPTRAB9A | |
| SCHEMBL30929976 | 0.83 | SMPD1 (0.54) | MRGPRX4NPC1MAPTRAB9ASMN1; SMN2 | |
| SCHEMBL32684052 | 0.81 | MAPT (0.46) | MRGPRX4NPC1GAAMAPTRAB9A | |
| SCHEMBL32684340 | 0.81 | MAPT (0.48) | MRGPRX4GAAMAPTRAB9ASMN1; SMN2 | |
| SCHEMBL30929977 | 0.79 | SLC6A3 (0.49) | MRGPRX4GAAMAPT | |
| SCHEMBL7815690 | 0.77 | PLAU (0.71) | PLAUERN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260070867-A1 | BINAPHTHYL COMPOUNDS AND THERMOPLASTIC RESINS | MITSUBISHI GAS CHEMICAL COMPANY, INC. (JP) | 2026-03-12 | — | — | US | disclosed |
| WO-2024115460-A1 | BINAPHTHYL COMPOUNDS AND THERMOPLASTIC RESINS | REUTER CHEMISCHE APPARATEBAU E.K. (DE) | 2024-06-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260070867-A1 | BINAPHTHYL COMPOUNDS AND THERMOPLASTIC RESINS | CBR1, CBR3, SCO2 | MRGPRX4 1763/4885PLAU 4680/4885ERN1 2782/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.